PharmAthene Presents New Data for Lyophilized RPA Anthrax Vaccine Showing Enhanced Immunogenicity

Published July 17, 2010

PharmAthene Presents New Data For Lyophilized RPA Anthrax Vaccine Showing Enhanced Immunogenicity
PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced results from a New Zealand White Rabbit study showing that its lyophilized recombinant Protective Antigen (rPA) anthrax vaccine was more immunogenic than a liquid formulation of rPA vaccine and produced a robust response with only 2 doses…
Read more on Medical News Today

GTC Biotherapeutics Regains US Rights to ATryn
ATryn is approved for use in patients with hereditary antithrombin deficiency, a rare and potentiall…
Read more on citybizlist Boston

Ten Million Deaths And 1 Million New HIV Infections Could Be Averted If Countries Meet HIV Treatment Targets
The new UNAIDS Outlook report outlines a radically simplified HIV treatment platform called Treatment 2.0 that could decrease the number of AIDS-related deaths drastically and could also greatly reduce the number of new HIV infections. Evidence shows that new HIV infections among young people, in the 15 countries most affected by HIV, are dropping significantly as young people embrace safer …
Read more on Medical News Today